IR Library | RaQualia Pharma Inc.

: Summary of Financial Results, Business Report, Mid-Term Business Plan

Summary of Financial Results

2012.05.14

Summary of Financial Results for the 1Q ended March 31, 2012
Business Report

2012.03.13

Business Report for the fourth fiscal year ended December 31, 2011
Mid-Term Business Plan

2012.02.23

Mid-Term Business Plan 2012 - 2014

Summary of Financial Results
- 2012.05.14
  Summary of Financial Results for the 1Q ended March 31, 2012
- 2011.11.11
  Summary of Financial Results for the 3Q ended September 30, 2011
Business Report
- 2012.03.13
  Business Report for the fourth fiscal year ended December 31, 2011
- 2012.02.16
  Summary of Business Report for the fourth fiscal year ended December 31, 2011
Mid-Term Business Plan
- 2012.02.23
  Mid-Term Business Plan 2012 - 2014

Corporate Information: CEO Message; Company Overview; Vision, Management Principle and Culture; Corporate Governance; Business Model; Origins of Our Corporate Name and Logo; Facilities; Access; Press Release
Research & Development: Collaboration; Partnering in Research; What are Research Tools?; Research Tool Licensing

Product Information: Anidulafungin; Ziprasidone; Dalbavancin; EP₄ Antagonist; Cyclooxygenase-2 (COX-2) Inhibitor; Ghrelin Receptor Agonist; 5-HT₄ Partial Agonist; Acid Pump Antagonist; 5-HT_2B Antagonist; CB₂ Agonist; Motilin Receptor Agonist; Licensing

Shareholder and Investor Information

To our Shareholders and Investors

Vision, Management Principle and Culture

Corporate Governance

Outline of Securities Matters

IR Related News

Understanding RaQualia Pharma! RaQualia FAQ: RaQualia's History; What does RaQualia Pharma do?; How Does RaQualia Earn Revenues?; What About Dividends?; What are RaQualia's strengths?; What Does the Future Hold for RaQualia Pharma?

Corporate Introduction Video
Contributions to Society: Corporate Contributions; Contributions to the Community; Press Release; Topics